Map Pharma maps next moves after FDA denied migraine drug; Pacira raising $58.5M in offering;

@FierceBiotech: Amazon hungers for genomics data after NIH pact. Story | Follow @FierceBiotech

@JohnCFierce: Another PhRMA fact from Dow Jones: 3,200 trials under way versus 2,400 in 2005. More | Follow @JohnCFierce

@RyanMFierce: AstraZeneca's Brennan says investors' calls for change have no impact on his standing. Anyone smell blood in the water? More | Follow @RyanMFierce

> Map Pharmaceuticals ($MAPP) updated investors on its plans to talk to U.S. regulators after the FDA issued a complete response to the Mountain View, CA-based company's application for approval for a migraine drug called Levadex. Release

> Pacira Pharmaceuticals ($PCRX) plans to sell 6 million shares of stock in a public offering that is expected to bring in about $58.5 million. Item

> Australian biotech ImmunAid raised AU$1 million in a first-round financing. The company is working on improving treatments with its research of the immune system. Release

Pharma News

@FiercePharma: Lilly chief: We can't cut our way out of this mess. Need new drugs, new sales, too--Bloomberg. Article | Follow @FiercePharma

> Novartis reports patient taking Gilenya developed rare brain disease. Article

> Bloomberg: Bayer to pay $110 million to get out from under 500 Yaz lawsuits. Story

> Merck's Propecia and Proscar linked to sexual dysfunction. More

Medical Devices News

 @FierceMedDev: Firewall Created to safeguard against medical-device hacking | Imperial Valley News. News | Follow @FierceMedDev

> Purdue/Princeton team creates firewall for medical devices. Story

> Tornier to consolidate facilities in Europe, U.S. More

> What can St. Jude expect post-Riata? Article

> NeuroLogica, Stryker enter BodyTom pact. News

And Finally… Alexza Pharmaceuticals ($ALXA) faces a major moment with the FDA, which is expected to take action on the company's bid for approval of Adasuve for patients with bipolar disorder and schizophrenia by May 4. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.